Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-265813
Filing Date
2025-11-05
Accepted
2025-11-05 08:06:06
Documents
106
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mnkd-20250930.htm   iXBRL 10-Q 4191860
2 EX-10.1 mnkd-ex10_1.htm EX-10.1 80848
3 EX-10.2 mnkd-ex10_2.htm EX-10.2 1650990
4 EX-31.1 mnkd-ex31_1.htm EX-31.1 15558
5 EX-31.2 mnkd-ex31_2.htm EX-31.2 15557
6 EX-32.1 mnkd-ex32_1.htm EX-32.1 11266
7 EX-32.2 mnkd-ex32_2.htm EX-32.2 11278
  Complete submission text file 0001193125-25-265813.txt   20141805

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mnkd-20250930.xsd EX-101.SCH 2689642
109 EXTRACTED XBRL INSTANCE DOCUMENT mnkd-20250930_htm.xml XML 3671903
Mailing Address 1 CASPER STREET DANBURY CT 06810
Business Address 1 CASPER STREET DANBURY CT 06810 818-661-5000
MANNKIND CORP (Filer) CIK: 0000899460 (see all company filings)

EIN.: 133607736 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-50865 | Film No.: 251451887
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)